Citations

Clear

912 citation(s) found for "Yu, Caroline".

Kidney donor profile index and post‐transplant health care utilization: Implications for value of transplant care delivery
Calderon, Esteban , Chang, James M. , Velazco, Cristine S. , Reddy, Kunam S. , Heilman, Raymond L. , Mathur, Amit K. , Mour, Girish K., Calderon, Esteban , Jadlowiec, Caroline , Mathur, Amit , Mour, Girish , Chang, Yu‐Hui , Jadlowiec, Caroline C.

Mayo Clinic

Clinical Transplantation | February 19, 2022 | Volume: 36 | Issue: 6 | Pages: No page available

10.1111/ctr.14618 | PMID 35182437 Get It

AbstractBackgroundCenters discard high kidney donor profile index (KDPI) allografts, potentially related to delayed graft function and prolonged hospital use by kidney transplant recipients (KTR). We sought to determine whether high KDPI KTRs have excess health care utilization.MethodsWe conducted a retrospective cohort study from a high‐volume center analyzing KTRs from January 3, 2011 to April 12, 2015 (n = 652). We measured differences in hospital use, emergency visits, and outpatient visits within the first 90 days between low (≤85%) versus high KDPI (>85%) KTRs, as well as long‐term graft function and patient survival.ResultsHigh (n = 107) and low KDPI (n = 545) KTRs had similar length of stay (median = 3 days, P = .66), and readmission rates at 7, 30, and 90 days after surgery (all, P > .05). High KDPI kidneys were not associated with excess utilization of the hospital, emergency services, outpatient transplant clinics, or ambulatory infusion visits on univariate or multivariate analysis (all, P > .05). Low KDPI KTRs had significantly better eGFR at 2 years (Low vs. High KDPI: 60.35 vs. 41.54 ml/min, P < .001), but similar 3‐year patient and graft survival (both, P > .09).ConclusionsHigh and low KDPI KTRs demonstrated similar 90‐day risk‐adjusted health care utilization, which should encourage use of high KDPI kidneys.
Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
Rauterkus, Grant, Hadadi, Agreen , Weipert, Caroline , Drusbosky, Leylah , Lilly, Michael B. , Naqvi, Syed Arsalan Ahmed , Bilen, Mehmet Asım , Barnett, Reagan M. , Gao, Xin Yuan , Bryce, Alan H. , Barata, Pedro C.

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 165-165

10.1200/jco.2022.40.6_suppl.165 Get It

165 Background: A prior study of patients with advanced cancers treated with immune checkpoint inhibitors (ICI) associated improved overall survival with tissue tumor mutational burden above the 80th percentile in each histology (tTMB-H). TMB can also reliably be calculated via liquid biopsy (bTMB), and trends higher than tTMB in analogous tumors. Here, we generate a plasma-informed benchmark for bTMB-H in advanced prostate cancer and report preliminary data from an ongoing multi-institutional case series of patients treated with ICI. Methods: Circulating tumor DNA (ctDNA) next generation sequencing (NGS) results from 3,504 patients with advanced prostate cancer who received a Guardant360 liquid biopsy within a 12-month period were analyzed. The 80th percentile of TMB was defined as the benchmark for bTMB-H in this cohort, and prevalence of microsatellite instability (MSI-H) was determined. Subsequently, clinical data were collected from patients across five institutions who received pembrolizumab based on bTMB scores or other tumor characteristics (i.e. CDK12 mutation). Results: Overall, mean and median bTMB were calculated as 12.34 mut/Mb and 8.61 mut/Mb, respectively (range: 0 – 1164.75 mut/Mb). The 80th percentile of bTMB was 13.4 mut/Mb and the 90th percentile was 16.6 mut/Mb. 2.6% of patients were both MSI-H and bTMB-H. No patients with bTMB < 13.4 mut/Mb (TMB-L) were found to be MSI-H. Ten patients from five institutions received pembrolizumab (8 monotherapy) after a median of 4.5 lines of prior therapy (Table). Four patients were MSI-H. The 3 patients in the cohort with PSA decreases > 50% had both MSI-H and bTMB ≥ 13.4 mut/Mb. Per RECIST criteria, disease was controlled (CR, PR, SD) in 6 of 7 (86%) patients with bTMB scores ≥ 13.4 mut/Mb. Conclusions: These data continue to affirm that ctDNA NGS is a practical and cost-effective means of assessing potential predictors of ICI activity in patients with advanced prostate cancer. Preliminary data from this growing cohort of patients who have received ICI guided by bTMB scores and other molecular parameters identified via ctDNA NGS, including MSI-H, demonstrate a clinical benefit from therapy. Further studies are warranted for contextualizing individual tumor bTMB scores with established, pathology-specific benchmarks.[Table: see text]
Duration Of Delayed Graft Function And Its Impact On Graft Outcomes In Deceased Donor Kidney Transplantation Running Head: Impact of Duration of Delayed Graft Function
Reddy, Kunam S. , Butterfield, Richard , Moss, Adyr A. , Khamash, Hassan A., Kodali, Lavanya , Misra, Suman , Heilman, Raymond L. , Budhiraja, Pooja , Jadlowiec, Caroline C.

Mayo Clinic

No container title available | February 9, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1277907/v1 Get It

Abstract Background. There is controversy regarding the impact of delayed graft function (DGF) on kidney transplant outcomes. We hypothesize that the duration of DGF, rather than DGF itself, is associated with long-term kidney graft function.Methods. We analyzed all deceased donor kidney transplants (DDKT) done at our center between 2008 to 2020 with DGF to determine factors associated with DGF duration as well as the impact of DGF duration on 1) acute rejection, BKV infection, progression of fibrosis on protocol biopsy, and death censored graft survival 2) resource utilization, including hospital length of stay and readmissions. DGF duration was assessed at three 14-day intervals: <14 DGF days, 14-27 DGF days, >28 DGF days.Results. There were 1714 DDKT were included, 59.4% (n=1018) had DGF. The median DGF duration was 10 days IQR (6,15). The majority of recipients (95%) had resolution of DGF within 28 days. Donor factors associated with DGF days were longer cold ischemia time, donor on inotropes, older age, donation after circulatory death, higher terminal creatinine, and hypertension. Recipient factors associated with increased DGF duration included male sex, length on dialysis before transplant, and higher body mass index. There were no differences in acute rejection events or interstitial fibrosis progression by 4 months when comparing DGF days. The median length of stay was 3 days. However, readmissions increased with increasing DGF duration. Death-censored graft survival was not associated with the length of DGF except when DGF lasted >28 days. Conclusions. Inferior graft survival was observed only in recipients of DDKT with DGF lasting beyond 28 days. DGF lasting <28 days had no impact on graft survival. Duration of DGF, rather than DGF itself, is associated with graft survival. Trial Registration. Retrospective study approved by Mayo Clinic IRB.
Immunotherapy as a Downstaging Tool for Liver Transplantation in Hepatocellular Carcinoma
Mathur, Amit K. , Borad, M.J., Lam‐Himlin, Dora , Corey, Rebecca, Iqbal, Sara , Okubo, Keita , Byrne, Thomas , Moss, Adyr A. , Aqel, Bashar , Chascsa, David M. , Lizaola-Mayo, Blanca C, Lam-Himlin, Dora M, Corey, Rebecca L, Byrne, Thomas J., Lizaola‐Mayo, Blanca , Jadlowiec, Caroline C. , Iqbal, Sara, Aqel, Bashar A.

Mayo Clinic

American Journal of Gastroenterology | February 8, 2022 | Volume: 116 | Issue: 12 | Pages: 2478-2480

10.14309/ajg.0000000000001391 | PMID 35134013 Get It

Dementia friendly community outreach improves research participation and dementia resource utilization among African Americans
Lucas, John A. , Robinson, Maisha T. , Willis, Floyd B. , Parfitt, Francine, Fudge, Michelle R., Wainwright, Jolita D., Graff‐Radford, Neill R. , Bergeron, Caroline D.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052088 Get It

AbstractBackgroundAfrican Americans are at greater risk of Alzheimer’s disease (AD) and AD‐related dementia (ADRD). They are also less likely to access dementia resources or participate in dementia research. The National Alzheimer’s Project Act (NAPA) calls for special attention to dementia‐related health disparities in high risk groups. Identifying effective tools to improve rates of dementia resource utilization and research participation by African Americans is essential to achieving dementia health equity.MethodTwo neighborhoods of Jacksonville, FL, defined by zip codes, were the focus of this study. Both zip codes have a large population of African American residents per 2010 US Census, and a history of hosting outreach activities by our Alzheimer’s Disease Research Center (ADRC). In one neighborhood, we modified the NAPA Dementia Friendly (DF) America toolkit to serve as a model of outreach. The second neighborhood served as a control (CON), in which we maintained our traditional outreach model of community‐based lectures. Primary outcome measures were: (1) enrollment in ADRC center‐related studies and (2) phone call volumes from individuals seeking dementia resource information. The outcomes in the DF and CON neighborhoods were compared via Fisher’s exact test to those in other zip codes in Jacksonville (OT).ResultIn the 18 months following implementation of the DF intervention, 54 African Americans enrolled in ADRC‐related research (19 DF, 3 CON, 32 OT), compared to 21 during the 18 months prior (2 DF, 0 CON, and 19 OT). The increase in DF residents enrolling in research following the intervention was statistically significant (p =0 .02) relative to OT residents. The increase observed in the CON residents was not statistically significant (p=1.0) compared to OT residents. Call volumes from African Americans increased from 13 prior to program implementation (all from OT) to 62 calls after implementation (22 DF, 1 CON, 39 OT). The increase among DF residents seeking information following the intervention was statistically significant (p =0.008) whereas the increase was not significant in the CON residents (p=0.54).ConclusionResults suggest that the NAPA DFA can be leveraged to improve dementia resource utilization and research participation among community‐dwelling African Americans.
Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial
Chung, Caroline , Brown, Paul D. , Wefel, Jeffrey S.

Mayo Clinic

Neuro-Oncology | January 31, 2022 | Volume: 24 | Issue: 5 | Pages: 851-851

10.1093/neuonc/noac028 | PMID 35460425 Get It

Device‐related infection associated with increased mortality risk in de novo transvenous implantable cardioverter‐defibrillator medicare patients
Liu, Yiyan , Griffiths, Robert I. , Knight, Bradley P. , Weiss, Raul , Mark, George E., Lambiase, Pier D. , Miller, Marc A. , Jacobsen, Caroline M., El-Chami, Mikhael F , Weiss, Raul , Miller, Marc A , Lambiase, Pier D , Knight, Bradley P , El‐Chami, Mikhael F. , Biffi, Mauro , Probst, Vincent , Baddour, Larry M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 23, 2022 | Volume: 33 | Issue: 4 | Pages: 725-730

10.1111/jce.15385 | PMID 35066954 Get It

AbstractIntroductionTransvenous implantable cardioverter‐defibrillators (TV‐ICD) infection is a serious complication that frequently requires complete device removal for attempted cure, which can be associated with patient morbidity and mortality. The objective of this study is to assess mortality risk associated with TV‐ICD infection in a large Medicare population with de novo TV‐ICD implants.MethodsA survival analysis was conducted using 100% fee‐for‐service Medicare facility‐level claims data to identify patients who underwent de novo TV‐ICD implantation between 7/2016 and 1/2018. TV‐ICD infection within 2 years of implantation was identified using International Classification of Disease, 10th Edition and current procedural terminology codes. Baseline patient risk factors associated with mortality were identified using the Charlson Comorbidity Index categories. Infection was treated as a time‐dependent variable in a multivariate Cox proportional hazards model to account for immortal time bias.ResultsAmong 26,742 Medicare patients with de novo TV‐ICD, 518 (1.9%) had a device‐related infection. The overall number of decedents was 4721 (17.7%) over 2 years, with 4555 (17%) in the noninfection group and 166 (32%) in the infection group. After adjusting for baseline patient demographic characteristics and various comorbidities, the presence of TV‐ICD infection was associated with an increase of 2.4 (95% CI: 2.08–2.85) times in the mortality hazard ratio.ConclusionThe rate of TV‐ICD infection and associated mortality in a large, real‐world Medicare population is noteworthy. The positive association between device‐related infection and risk of mortality further highlights the need to reduce infections
Letter to the Editor. The value of an engaged endocrine practice may outweigh patient factors
Gompel, Jamie J. Van, Atkinson, John L. D., Choby, Garret, Bancos, Irina, Davidge-Pitts, Caroline J., Erickson, Dana, Gompel, Jamie J. Van, Atkinson, John L. D., Choby, Garret, Bancos, Irina, Davidge-Pitts, Caroline J., Erickson, Dana

Mayo Clinic

Journal of Neurosurgery | January 21, 2022 | Volume: 136 | Issue: 5 | Pages: 1504-1505

10.3171/2021.11.jns212584 | PMID 35061989 Get It

Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.
Gallois, Claire , Meyers, Jeffrey P., Gramont, Aimery de , Sobrero, Alberto F. , Haller, Daniel G. , Shields, Anthony F. , Boukovinas, Ioannis , Sougklakos, Ioannis, Papamichail, Demetris, Shi, Qian , Iveson, Timothy , Alberts, Steven R. , Oki, Eiji , Kelly, Caroline , Labianca, Roberto , Sinicrope, Frank A. , Yoshino, Takayuki , Meyerhardt, Jeffrey A. , André, Thierry , Taı̈eb, Julien

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 11-11

10.1200/jco.2022.40.4_suppl.011 Get It

11 Background: Six months of oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) remains a standard in high-risk stage III patients. Early treatment discontinuation (ETD) could worsen the prognosis. In addition, there is current lack of data on the prognostic impact of early oxaliplatin only discontinuation (EOD). Methods: We studied the prognostic impact of ETD and EOD in patients with stage III CC who participated in 11 relevant clinical trials of the ACCENT and IDEA databases, where patients were planned to receive 6 months of adjuvant fluoropyrimidine plus oxaliplatin (FOLFOX or CAPOX). ETD was defined as discontinuation of treatment before 75% of cycles of chemotherapy. EOD was defined as discontinuation of oxaliplatin only, while continuing the fluoropyrimidine, before 75% of cycles of oxaliplatin. Association between ETD/EOD and overall survival (OS) and disease-free survival (DFS) was assessed by Cox model adjusted for prognostic factors. Results: ETD analysis included 10,444 patients (FOLFOX n = 7,033; CAPOX n = 3,411), with 20.9% of patients with ETD (17.8% with FOLFOX and 27.2% with CAPOX, p < 0.001). Out of 7,243 patients, 18.8% experienced EOD (17.4% FOLFOX versus 21.4% with CAPOX, p < 0.001). Compared to patients without ETD or EOD, patients with ETD or EOD were statistically more likely to be women, older, with higher ECOG-PS ≥ 1, and in addition for ETD, a Body Mass Index (BMI) < 18.5 kg/m2. In multivariate analyses, ETD was associated with a decrease in DFS and OS in the overall population (HR: 1.40 95%CI 1.23-1.58, p < 0.001 and HR: 1.51 95%CI 1.31-1.74, p < 0.001, respectively). The same pattern was present with FOLFOX and CAPOX regimen, and also in low-risk and high-risk groups for each regimen with the exception of the CAPOX regimen in the low-risk group for DFS and OS. By contrast, EOD was not associated with reduced DFS or OS in the overall population (HR: 1.10 95%CI 0.77-1.58, p = 0.6 and HR: 0.97 95%CI 0.62-1.52, p = 0.9, respectively), in the low-risk group (HR: 0.97 95%CI 0.56-1.66, p = 0.9 and HR: 0.97 95%CI 0.51-1.82, p = 0.9, respectively) and high-risk group (HR: 1.22 95%CI 0.74-2.02, p = 0.4 and HR: 1.05 95%CI 0.53-2.08, p = 0.9, respectively) and for all subgroups of regimen. Conclusions: In patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III CC, ETD was associated with a decrease in DFS and OS. By contrast, EOD was not significantly associated with poorer outcomes. In case of relevant neurotoxicity during a 6 months schedule, these data are not in favor of continuing oxaliplatin beyond 75% of planned cycles of adjuvant chemotherapy, and demonstrate that fluoropyrimidines remain the cornerstone of adjuvant chemotherapy in localized CC.
Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis
Murphy, Neil , Song, Mingyang , Papadimitriou, Nikos , Carreras‐Torres, Robert , Langenberg, Claudia , Martin, Richard M. , Tsilidis, Konstantinos K. , Barroso, Inês , Chen, Ji , Vincent, Emma E. , Cotterchio, Michelle , Gruber, Stephen B. , Pai, Rish K. , Perez‐Cornago, Aurora , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Vodička, Pavel , Wu, Anna H. , Peters, Ulrike , Gunter, Marc J. , Frayling, Timothy M , Bull, Caroline J , Vincent, Emma E , Gruber, Stephen B , Pai, R K , Perez-Cornago, Aurora , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Chan, Andrew T , Gunter, Marc J , Murphy, Neil , Martin, Richard M , Song, Mingyang , Carreras-Torres, Robert , Tsilidis, Konstantinos K , Papadimitriou, Nikos , Vodicka, Pavel , Bull, Caroline J. , Newcomb, Polly A. , Wolk, Alicja , Chan, Andrew T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 14, 2022 | Volume: 114 | Issue: 5 | Pages: 740-752

10.1093/jnci/djac011 | PMID 35048991 Get It

Abstract Background Glycemic traits—such as hyperinsulinemia, hyperglycemia, and type 2 diabetes—have been associated with higher colorectal cancer risk in observational studies; however, causality of these associations is uncertain. We used Mendelian randomization (MR) to estimate the causal effects of fasting insulin, 2-hour glucose, fasting glucose, glycated hemoglobin (HbA1c), and type 2 diabetes with colorectal cancer. Methods Genome-wide association study summary data were used to identify genetic variants associated with circulating levels of fasting insulin (n = 34), 2-hour glucose (n = 13), fasting glucose (n = 70), HbA1c (n = 221), and type 2 diabetes (n = 268). Using 2-sample MR, we examined these variants in relation to colorectal cancer risk (48 214 case patient and 64 159 control patients). Results In inverse-variance models, higher fasting insulin levels increased colorectal cancer risk (odds ratio [OR] per 1-SD = 1.65, 95% confidence interval [CI] = 1.15 to 2.36). We found no evidence of any effect of 2-hour glucose (OR per 1-SD = 1.02, 95% CI = 0.86 to 1.21) or fasting glucose (OR per 1-SD = 1.04, 95% CI = 0.88 to 1.23) concentrations on colorectal cancer risk. Genetic liability to type 2 diabetes (OR per 1-unit increase in log odds = 1.04, 95% CI = 1.01 to 1.07) and higher HbA1c levels (OR per 1-SD = 1.09, 95% CI = 1.00 to 1.19) increased colorectal cancer risk, although these findings may have been biased by pleiotropy. Higher HbA1c concentrations increased rectal cancer risk in men (OR per 1-SD = 1.21, 95% CI = 1.05 to 1.40), but not in women. Conclusions Our results support a causal effect of higher fasting insulin, but not glucose traits or type 2 diabetes, on increased colorectal cancer risk. This suggests that pharmacological or lifestyle interventions that lower circulating insulin levels may be beneficial in preventing colorectal tumorigenesis.